

Docket No.: PH114205.1701/KMZ15101.01701  
Customer No. 27160

PATENT/OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Yu HUA

Serial No. 09/832,865

Filed: April 12, 2001



RECEIVED

APR 03 2002

TECH CENTER 1600/2900

Group Art Unit: 1633

Examiner: Anjum I. Rishi

DFT

For: REGULATION OF SYSTEMIC IMMUNE RESPONSES UTILIZING SOLUBLE CD40

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D. C. 20231

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Some of the references were cited in the International Search Report dated 10 December 2001 of this application and in related applications. No further elaboration is believed necessary. Copies of the search report and cited art are submitted herewith in accordance with 37 C.F.R. § 1.98(a).

APR 01 2002

PATENT/OFFICIAL



RECEIVED

APR 03 2002

TECH CENTER 1600/2900

LIST OF ART CITED BY APPLICANT (PTO-1449)		ATTY. DOCKET NO. 114205.1701	SERIAL NO. 09/832,865
		APPLICANT Yu HUA	
		FILING DATE April 12, 2001	GROUP 1633

U.S. PATENT DOCUMENTS

Examiner's initials		PATENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	A	U.S. 6,187,306B1	13 Feb 2001	Pardoll et al.			
	B	U.S. 5,904,920	18 May 1999	Dranoff et al.			
	C	U.S. 5,098,702	24 Mar 1992	Zimmerman et al.			
	D	U.S. 5,078,996	7 Jan 1992	Conlon, III et al.			
	E						
	F						

FOREIGN PATENT DOCUMENTS

G	WO/92/05262	2 Apr 1992	Johns Hopkins; Frost, P. et al.				
H	WO/94/04570	3 Mar 1994	Schering Corp.; Heath, A. et al.				
I	WO/99/43839	2 Sep 1999	Univ. of Pennsylvania; Kim J.J. et al.				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

J	International Search Report PCT/US01/12003
K	Fearon et al., "Interleukin-2 production by tumor cells bypasses T-helper function in the generation of an antitumor response"; Cell, vol. 60, 1990: 397-403.
L	Dranoff et al., "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity"; Proc. Natl. Acad. Sci., vol. 90, 1993: 3539-43.
M	Ridge et al., "A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell"; Nature, vol. 393, 1998: 474-77.
N	Gunrunathan et al., "CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infections and tumor challenge"; J. Immunol., vol. 161, 1998: 4563-71.
O	Schrewe et al., "Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression"; Mol. Cell. Biol., vol. 10, 1990: 2738-48.
P	Torres et al., "Differential increase of an alternatively polyadenylated mRNA species of murine CD40 upon B lymphocyte activation"; J. Immunol., vol. 148, 1992: 620-26(2).
Q	Sotomayor et al., "Conversion of Tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40"; Nature Med., vol. 5, 1999: 780-87.
R	Tan et al., "Interleukin-12 cDNA skin transfection potentiates human papillomavirus E6 DNA vaccine-induced antitumor immune response"; Cancer Gene Therapy, vol. 6, no. 4, 1999: 331-39.
S	Pape et al., "Direct evidence that functionally impaired CD4+ T-cells persist in vivo following induction of peripheral tolerance"; J. Immunol., vol. 160, no. 10, 1998: 4719-29.
T	Lode et al., "Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy"; Blood, vol. 91, 1998: 1706-15.
U	Mackey, M.F. et al., "Dendritic cells require maturation via CD40 to generate protective antitumor immunity"; J. Immunol., vol. 161, no. 5, 1998: 161-65.
V	
W	
X	
Y	
Z	

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.